Abstract:Valentina Zanuso, 1, 2 Angelo Pirozzi, 1, 2 Rita Balsano, 2 Tiziana Pressiani, 2 Lorenza Rimassa 1, 2 1 Department of Biomedical Sciences, Humanitas University, Milan, Italy; 2 Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy Correspondence: Lorenza Rimassa, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy, Tel +39 02 82244573, Fax +39 02 82244590, Email Hepatocellular carcinoma (HCC) is one of the most common leading causes of cancer death worldwide. As most patients are diagnosed with advanced disease, systemic therapy remains the backbone of treatment. In recent years, we have witnessed the transformation of advanced HCC treatment landscapes from single-agent targeted therapies to immunotherapy combinations, with atezolizumab plus bevacizumab becoming the new first-line standard of care with an increase in overall survival, progression-free survival, and objective response rate compared to sorafenib, and a positive impact on quality of life. Although the efficacy and safety of this combination have been confirmed regardless of ethnicity, age, and etiology, only a subgroup of patients seems to benefit the most from this treatment. Currently, predictive serum and tissue biomarkers to select patients who are most likely to respond to atezolizumab plus bevacizumab are lacking. Moreover, the optimal subsequent therapy for patients who progress on first-line atezolizumab plus bevacizumab remains unknown, clinical trials are ongoing, and real-world data are needed to determine the most effective treatment sequence. Importantly, careful evaluation of bleeding risk and preservation of adequate liver function are fundamental to improve patients' prognosis, especially when subsequent treatments are administered. Keywords: HCC, immune checkpoint inhibitors, atezolizumab, bevacizumab, safety, efficacy Hepatocellular carcinoma (HCC) is a global health issue with increasing incidence and mortality worldwide. It generally emerges within a chronic liver disease condition, which includes chronic viral hepatitis (hepatitis C virus [HCV] and hepatitis B virus [HBV]), alcoholic cirrhosis, metabolic conditions (metabolic dysfunction-associated fatty liver disease [MAFLD], previously known as non-alcoholic fatty liver disease [NAFLD], metabolic dysfunction-associated steatohepatitis [MASH], previously known as non-alcoholic steatohepatitis [NASH], diabetes), and aflatoxin exposure. 1,2 Unfortunately, most patients are diagnosed with advanced disease or progress after locoregional approaches and therefore, systemic therapies represent the backbone of treatment. Systemic treatment is indicated for patients with advanced or intermediate HCC that are unsuitable for locoregional treatment and with preserved liver function. 1,3 After more than a decade of multi-kinase inhibitors (MKIs) monopoly, in 2020, the combination of atezolizumab plus bevacizumab became the new first-line standard of care, introducing immunotherapy in advanced HCC and contributing to the reshaping of HCC treatment algorithm, with an increase in survival. In this review, we will shed light on atezolizumab plus bevacizumab, starting from clinical studies that led to the approval of this combination, focusing on safety and efficacy data, and then moving to more recent exploratory analyses and real-life studies, evaluating future perspectives of HCC treatment strategies and sequential therapies. Moreover, we want to highlight the urgent need to identify predictive biomarkers to properly select patients and obtain durable clinical benefits in those who are more likely to respond, sparing adverse events in non-responders. Sorafenib, a MKI, has been the mainstay of advanced or metastatic HCC treatment since 2007. 4,5 A decade later, new targeted agents have been approved in either the first or subsequent lines. In detail, lenvatinib was found to be non-inferior to sorafenib in the first-line setting. 6 Regorafenib, cabozantinib, and ramucirumab were approved in the refractory context, with cabozantinib showing efficacy even in the third line. 7–9 Furthermore, regorafenib demonstrated efficacy in a sorafenib-tolerant population, whereas ramucirumab showed improved survival in patients with alpha-fetoprotein (AFP) levels ≥400 ng/mL at baseline. 7,9 Recently, the advent of immunotherapy has dramatically changed the first-line therapeutic scenario, resulting in a widening of treatment opportunities. In 2020, the combination of the anti-programmed death ligand-1 (PD-L1) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) bevacizumab became the new first-line standard of care, outperforming sorafenib. 10–12 S -Abstract Truncated-

The synergic effect of metformin with atezolizumab/ bevacizumab in masld hcc patients: a retrospective study from arte multicentric Italian dataset

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC

Aetiology of hepatocellular carcinoma and response to immunotherapy: is the problem inherent in the classification of non-viral disease?

Abstract CT044: Genomic Correlates of Clinical Benefits from Atezolizumab Combined with Bevacizumab Vs. Atezolizumab Alone in Patients with Advanced Hepatocellular Carcinoma (HCC)

Effect of metformin on hepatocellular carcinoma patients with type II diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study

Atezolizumab with or Without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): an Open-Label, Multicentre, Phase 1b Study

Metformin: a modulator of bevacizumab activity in cancer? A case report

Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes

Comparison of the treatment effect between lenvatinib and atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in pathologically diagnosed metabolic dysfunction–associated steatotic liver disease.

Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis

Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

Abstract PO1-25-12: Metformin enhances response to chemotherapy combined with immunotherapy in a triple negative breast cancer in vivo model

Meta-analysis: the Efficacy of Metformin and Other Anti-Hyperglycemic Agents in Prolonging the Survival of Hepatocellular Carcinoma Patients with Type 2 Diabetes.

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma

Efficacy of Αtezolizumab-Βevacizumab in BCLC-C cirrhotic patients with hepatocellular carcinoma according to the type of disease progression, the type of BCLC-C and liver disease severity

Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway